Meridian Bioscience, Inc. (NASDAQ:VIVO) CEO Acquires $154,600.00 in Stock

Meridian Bioscience, Inc. (NASDAQ:VIVO) CEO John P. Kenny bought 20,000 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were bought at an average cost of $7.73 per share, with a total value of $154,600.00. Following the completion of the transaction, the chief executive officer now owns 198,324 shares in the company, valued at $1,533,044.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Meridian Bioscience stock traded up $0.10 during trading hours on Tuesday, reaching $8.05. 397 shares of the company’s stock were exchanged, compared to its average volume of 347,809. The company has a quick ratio of 4.75, a current ratio of 6.93 and a debt-to-equity ratio of 0.40. The firm’s 50 day simple moving average is $9.56 and its 200 day simple moving average is $10.70. Meridian Bioscience, Inc. has a twelve month low of $7.62 and a twelve month high of $19.84. The firm has a market capitalization of $337.42 million, a PE ratio of 11.69 and a beta of 0.37.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.04. Meridian Bioscience had a return on equity of 15.89% and a net margin of 12.13%. The firm had revenue of $50.80 million during the quarter, compared to the consensus estimate of $50.57 million. During the same period last year, the business posted $0.20 EPS. The business’s revenue was down 4.3% compared to the same quarter last year. Analysts anticipate that Meridian Bioscience, Inc. will post 0.31 EPS for the current year.

Several brokerages recently issued reports on VIVO. ValuEngine raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Canaccord Genuity reaffirmed a “sell” rating and set a $9.00 target price on shares of Meridian Bioscience in a research report on Wednesday, July 31st. Finally, Zacks Investment Research lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $11.25.

A number of institutional investors have recently modified their holdings of the business. UBS Asset Management Americas Inc. grew its holdings in Meridian Bioscience by 4.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 28,530 shares of the company’s stock worth $339,000 after acquiring an additional 1,163 shares during the period. Swiss National Bank grew its stake in shares of Meridian Bioscience by 2.2% in the 2nd quarter. Swiss National Bank now owns 79,000 shares of the company’s stock valued at $939,000 after buying an additional 1,700 shares during the period. 6 Meridian grew its stake in shares of Meridian Bioscience by 4.9% in the 2nd quarter. 6 Meridian now owns 42,384 shares of the company’s stock valued at $504,000 after buying an additional 1,964 shares during the period. Coastal Capital Group Inc. acquired a new stake in shares of Meridian Bioscience in the 2nd quarter valued at about $25,000. Finally, Pacer Advisors Inc. grew its stake in shares of Meridian Bioscience by 19.0% in the 3rd quarter. Pacer Advisors Inc. now owns 14,734 shares of the company’s stock valued at $140,000 after buying an additional 2,354 shares during the period. Hedge funds and other institutional investors own 88.49% of the company’s stock.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Featured Article: Why Invest in High-Yield Dividend Stocks?

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit